OTTAWA, May 20, 2015 /CNW/ - The 2015 Access to Medicines report will be unveiled tomorrow, revealing how Canada lags compared to other countries in access to new medicines in public drug plans, and the impact on patients that need access to these new treatments.
| Date |
Thursday, May 21, 2015 |
| Time |
10:00 am |
| Location |
National Press Theatre |
About Canada's Research-Based Pharmaceutical Companies
Canada's Research-Based Pharmaceutical Companies is the national association representing the voice of Canada's innovative pharmaceutical industry. We serve our membership by advocating for policies that enable the discovery, development and delivery of innovative medicines and vaccines to improve the lives of all Canadians. We support our memberships' commitment to being a valued partner in the Canadian healthcare system. We represent more than 50 companies investing over $1-billion in R&D annually, fuelling Canada's knowledge-based economy, while contributing over $3-billion overall to Canada's economy. Guided by our Code of Ethical Practices, we work with governments, private payers, healthcare professionals and stakeholders in a highly ethical manner.
SOURCE Canada's Research-Based Pharmaceutical Companies (Rx&D)
Image with caption: "Access to New Medicines in Public Drug Plans: Canada and Comparable Countries (CNW Group/Canada's Research-Based Pharmaceutical Companies (Rx&D))". Image available at: http://photos.newswire.ca/images/download/20150521_C5161_PHOTO_EN_16779.jpg
Sarah Douglas, Media Relations, Rx&D, Telephone: 613-883-7250, E-mail: [email protected]
Share this article